1.An Alignment Technique of Body Gravity for Fit of Prosthesis
Feng ZHENG ; Ming ZHU ; Xu-hui ZOU
Chinese Journal of Rehabilitation Theory and Practice 2015;21(7):757-759
Objective To develop an alignment technique based on the movement of body gravity center. Methods As join forces in the system of balance is zero, the position of body gravity center can be calculated by body gravity which is taken from weight sensors, by the special software. Meanwhile, the position of body gravity will be sent to control unit, which can be transformed to driving signal of motor. The sliding table with laser, linked to motor, can make pursuit movement following with body gravity. A precise alignment can be made as the movement of body gravity. The balance function test is also used to make an assistant estimate for the alignment. Results and Conclusion An alignment technique has been developed for the fit of prosthesis and orthotics.
2.A system review of randomized controlled trials on treating chronic stable angina by rhodiola.
Jian-Feng CHU ; Guang-Wen WU ; Guo-Hua ZHENG ; Feng ZHENG ; Jian-Feng XU ; Jun PENG ; Zhen-Feng HONG
Chinese Journal of Integrated Traditional and Western Medicine 2014;34(8):940-946
OBJECTIVETo systematically assess the efficacy and safety of Rhodiola in treating chronic stable angina pectoris.
METHODSOur group searched the Cochrane library, PubMed, Embase, Chinese biomedical literature database (CBM), VIP database (VIP), Chinese Journal Full-text Database (CNKI) for the literature published in English and Chinese till April 2013. Randomized controlled trials (RCTs) were included on the therapeutic effect of Rhodiola or Rhodiola plus conventional Western medicine in comparison with the conventional Western medicine treatment on stable angina. Data were extracted according the data extraction form. The literature methodological quality was assessed by using the Cochrane handbook, and data analyzed by Rev-Man 5.2 Software for Meta-analysis. The effect indicators of outcomes was expressed by odds ratio (OR) and 95% CI.
RESULTSA total of 7 randomized controlled trials, 662 cases of stable angina pectoris patients met the inclusion criteria and all published in Chinese, without one scientific design and high quality literature. Compared with the conventional Western medicine treatment, combined with oral administration of Rhodiola could improve the efficiency of anti-angina (OR = 2.49, 95% CI: 1.02 - 6.09). Combined with intravenous infusion of Rhodiola could also improve the efficacy of angina pectoris (OR = 4.86, 95% CI: 2.4 - 9.82). Oral administration of Rhodiola couldn't improve ECG efficacy (OR = 1.25, 95% CI: 0.67 - 2.34). Intravenous infusion of Rhodiola could improve the clinical efficacy (OR = 2.94, 95% CI: 1.61 - 5.35). Combined with the conventional treatment, intravenous infusion of Rhodiola could improve the whole blood viscosity (low and high shear rates) and inverse variance (IV) (-1.36 and -0.99, 95% CI: -1.65 - 1.07 and -1.26 - 0.71), but could not reduce serum fibrinogen and D-dimer level. The incidence rate of adverse reactions was higher than that of the conventional treatment combined with Rhodiola (OR = 0.1, 95% CI: 0.02 - 0.51).
CONCLUSIONSOn the basis of routine treatment, Rhodiola could further improve patients' symptoms. Combined with intravenous medication, Rhodiola could increase the ECG improvement rate, and reduce adverse reactions. But the methodological quality of included studies was poor, the number of samples was small, and influence factors such as the intervention period was short. This conclusion needs scientific and rational design in a larger sample, multicenter clinical trial to verify.
Angina, Stable ; drug therapy ; Chronic Disease ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Randomized Controlled Trials as Topic ; Rhodiola ; Treatment Outcome
3.Combined effects of fluoride and arsenite on the expression of Runx-related transcription 2 mRNA in bone of rats
Chong ZHENG ; Feng HONG ; Degan XU ; Yali QIAN
Chinese Journal of Endemiology 2014;33(2):141-144
Objective To explore the combined effects of fluoride and arsenite on the expression of Runx-related transcription 2 (Runx2) mRNA in bone of Sprague Dawley (SD) rats.Methods Fifty four SD rats were selected[body mass(109.71 ± 10.52)g,half male and half female].3 × 3 Factorial experimental design was used to evaluate the combined effects of fluoride and arsenite on the expression of Runx2 mRNA by random number talbe.Rats were exposed to NaF,NaAsO2 and NaF plus NaAsO2 for 6 months by oral perfusion at gradient doses,respectively:the control group(0 mg/kg NaF + 0.0 mg/kg NaAsO2),the low fluoride group(5 mg/kg NaF),the high fluoride group(20 mg/kg NaF),the low arsenite group(2.5 mg/kg NaAsO2),the high arsenite group(10.0 mg/kg NaAsO2),the low fluoride low arsenite group(5 mg/kg NaF + 2.5 mg/kg NaAsO2),the high fluoride low arsenite group(20 mg/kg NaF + 25 mg/kg NaAsO2),the low fluoride high arsenite group(5 mg/kg NaF + 10.0 mg/kg NaAsO2) and the high fluoride high arsenite group(20 mg/kg NaF + 10.0 mg/kg NaAsO2).The expression of Runx2 mRNA was determined by quantitative real-time RT-PCR.Results The expressions of Runx2 mRNA in the control,low fluoride,high fluoride,low arsenite,high arsenite,low fluoride low arsenite,low fluoride high arsenite,high fluoride low arsenite and high fluoride high arsenite groups were 1.024 ± 0.015,1.377 + 0.014,1.587 ± 0.012,1.182 ± 0.015,1.343 ± 0.010,1.444 ± 0.019,1.504 ± 0.013,1.608 ± 0.013 and 1.714 + 0.009,respectively.The expressions of Runx2 mRNA in experimental groups were higher than those in control group (all P < 0.05),fluoride and arsenite were positively correlated with the expression of Runx2 mRNA(all P < 0.01),and there was a dose-response relationship between Runx2 mRNA and fluoride-arsenite levels.Factorial analysis showed that fluorine or arsenic alone could affect the expression level of Runx2(F =46.967,8.317,all P < 0.05),and there was a interaction between fluorine and arsenic to the expression of Runx2 mRNA (F =105.271,P < 0.01).Conclusion Fluoride or arsenic could promote the expression of Runx2 mRNA in bone of rats; there is an interaction between fluorine and arsenic to the expression of Runx2 mRNA.
4.A clinical study in undifferentiated small cell carcinoma of the esophagus
Zhun WANG ; Wei FENG ; Xiao ZHENG ; Guan LIU ; Yujin XU
China Oncology 2000;0(06):-
Background and purpose:Esophageal cancer(EC) is one of the most common cancers that account for cancer-related deaths and over 400,000 new cases has been diagnosed per year.The morbility of small cell carcinoma of the esophagus(SCEC) is very low.This paper was to study was the clinical characteristics,treatment and prognosis of undifferentiated small cell carcinoma of the esophagus(SCEC).Methods:From 1961 to 2003,743 patients with SCEC were treated in different hospitals.The number of small cell carcinoma of the esophagus seen accounted for 1.38% of esophageal cancer treated in those hospitals in the same period.the average age was 56.8(range,51 to 66).511 of patients were male and 232 female.2 of them had primary tumor in the cervical proportion of the esophagus,68 in the upper thoracic proportion,420 in the mid thoracic proportion,252 in the lower proportion and 1 in the whole esophagus.88 patients were treated by surgery alone,23 by radiotherapy alone,24 patients by chemotherapy alone and all other of patients were treated by combined modality.Results:The median survival was 12.4 months for all patients,with 10.8 months for surgery,6.2 months for radiotherapy,6.6 months for chemotherapy,14.7 months for surgery combined with radiotherapy,16.1 months for surgery combined with chemotherapy,12.3 months for chemoradiotherapy and 16.2 months for surgery combined with chemoradiotherapy,respectively.The survival rates at 1,2,3,4,and 5 years were 56.4%、27%、19.3%、11.1%、(9.7%) for the whole group,respectively.Conclusions:We recommend that combined modality should be used for SCEC.The combination of surgery and multi-drug chemotherapy may improve the treatment outcomes for the patients with early stage SCEC.
5.Effects of sevoflurane pretreatment on lung metastasis of mouse Lewis lung cancer cells
Feng XU ; Tao ZHANG ; Xueqing ZHENG ; Chengxiang YANG ; Hua LIANG
The Journal of Clinical Anesthesiology 2017;33(1):71-73
Objective To observe the effects of sevoflurane pretreatment on lung metastasis of mouse Lewis lung cancer (LLC)cells.Methods Mouse LLC cells were inoculated in culture plate. After being cultured for 24 h the cells were randomly divided into four groups:group control (CC), group 1% sevoflurane (SC1),group 2% sevoflurane (SC2),and group 3% sevoflurane (SC3).Cells of group SC1-3 were exposed to 1%,2%,3% sevoflurane for 4 h respectively,cells of group CC were exposed to 95%O 2-5%CO 2 mixture air,and were then cultured for another 24 h.The invasive activity of cells was determined by Transwell assay.The migration of cells was evaluated by wound scratch assay.The expression of MMP-2 and MMP-9 in cells were detected by ELISA.Thirty-two C57BL/6 mice were divided into four groups (n = 8):group control (CM),group 1% sevoflurane (SM1),group 2% sevoflurane (SM2),and group 3% sevoflurane (SM3).LLC cells of group SC1-3 were injected into caudal vein of mouse in group SM1-3 respectively.Cells of group CC were injected into mouse of group CM.Lung metastasis inhibitory rates were evaluated after 3 weeks. Results Compared with group CC,the invasive activity and migration of cells in group SC1-3 were decreased significantly,group SC1 >group SC2 >group SC3 (P <0.05 );the protein expression of MMP-2 and MMP-9 was significantly down-regulated with sevoflurane concentration increased,group SC1 >group SC2>group SC3 (P <0.05).Compared with group CM,lung metastasis inhibitory rates of group SM1-3 were increased significantly,group SM1 < group SM2 < group SM3 (P < 0.05 ). Conclusion Sevoflurane can inhibit the lung metastasis of mouse LLC cells,which maybe through down-regulating the expression of MMP-2 and MMP-9 in mouse LLC cells.
6.Effect of oxycodone combined flurbiprofen ester in the treatment of postoperative analgesia after thoracic surgery
Chabing LI ; Feng XU ; Wei WANG ; Kesong ZHENG
The Journal of Clinical Anesthesiology 2016;32(12):1183-1185
Objective To observe the efficacy of oxycodone or fentanyl combined with flurbi-profen esters (FA)for postoperative analgesic after thoracic surgery.Methods Eighty patients,53 males and 24 females,aged 40-65 years,ASA physical status Ⅰ-Ⅲ,undergoing elective thoracotomy surgery,randomly divided into two groups (n =40 each).Oxycodone 0.1 mg/kg (group O)or fenta-nyl 1 μg/kg (group F)were intravenously injected 1 5 minutes before the end of surgery.Each patient was given PCIA,with solution including oxycodone 0.8 mg/kg plus FA 4 mg/kg plus ondansetron 8 mg plus 0.9% NaCl (1 50 ml)in group O and fentanyl 8 μg/kg plus FA 4 mg/kg plus ondansetron 8 mg plus 0.9% NaCl (1 50 ml)in group F.The coughing and resting visual analogue scale (VAS), Ramsay score at 2,6,12,24,36 and 48 hours after operation,complications,the times of patient controlled pressing and requirement for rescue analgesic were evaluated.Results Compared with group F, the resting and coughing VAS at 2, 6, 12, 24, 36 and 48 hours after operation, requirement for rescue analgesic,the incidence of nausea and vomiting and the times of patient con-trolled pressing were significantly lower in group O (P <0.05).There was no significantly difference in the Ramsay score.Conclusion It is effective that the patients undergoing thoracic surgery used the PCIA of oxycodone combined FA to control the postoperative pain, and analgesic effect more excellent than fentanyl combined FA,and with fewer side effects.
8.Effects of herbs with function of activating blood circulation and detoxication on serum infl ammatory markers and blood lipids in stable patients with coronary heart disease
Feng ZHENG ; Mingxue ZHOU ; Hao XU ; Keji CHEN
China Journal of Traditional Chinese Medicine and Pharmacy 2006;0(09):-
Objective:To observe the additional effects of Xin Qing-ning Tablets,a representative herb with the effect of activating blood circulation and detoxication(ABCD) consisting of rhubarb extractives,on the serum in ammatory markers and blood lipids in stable coronary heart disease(CHD) patients receiving standardized statins treatment.Methods:Thirty stable CHD patients were randomized to three groups(10 in each group):the control group treated with standardized statins;the ABC and ABCD group,treated with Dan Qi Tablets or Xin Qing-ning Tablets respectively in addition to standardized statins treatment.After one month treatment,the concentrations of high-sensitivity C reaction protein(hs-CRP),Tumor necrosis factor-?(TNF-?) in serum,blood lipid and blood-stasis syndrome score(BSSS) of CHD patients before and after treatment were determined.Results:The ABCD group showed superior e ects in reducing the concentration of hs-CRP in serum[a di erence of(6.83?4.99)mg/L]as compared with the control group(1.90?2.15)mg/L and the ABC group(1.49?1.48)mg/L(P
9.Expression of MMP-2 and TIMP-2 in the Traumatic PVR Retina of SD Rats.
Guoxing XU ; Chunyan FENG ; Xuedong ZHENG ; Qing HE
Journal of Medical Research 2006;0(02):-
Objective To investigate the expression of MMP-2 and TIMP-2 during the course of traumatic PVR treated with GM6001 and without GM6001,and to explore the potential role of MMP-2 and TIMP-2 during the course of traumatic PVR and to evaluate the effect of GM6001 on traumatic PVR prevention and treatment.Methods 360 SD rats were divided randomly into three groups: normal control group,the traumatic PVR group,the traumatic PVR treated with GM6001 group.The normal control group was intravitreous injected with normal saline.The traumatic PVR group was intravitreous injected with the PRP.The traumatic PVR treated with GM6001 group was intravitreous injected with the PRP and GM6001.The expression of MMP-2 and TIMP-2 were qualitativly and semiquantitativly analyzed with immunohistochemistry on day 1,3,7,14,21 and 28.Results 1.The results of immunohistochemistry showed that the expression of MMP-2,TIMP-2 was mainly located in the photoreceptor cells layer,out plexiform layer,inner plexiform layer and nerve fiber layer.2.The expression of MMP-2 in the normal group and the traumatic PVR treated with GM6001 group was weak at all time.The differences were statistical significance as compared with the normal group and the traumatic PVR treated with GM6001 group(P
10.Study on the Sustained Release of BSA from Chitosan-OREC/BSA Films Coated Mats in Vitro
Ruifen XU ; Qingxia ZHAO ; Xin CHEN ; Xingxing ZHENG ; Xuyang FENG
Journal of Modern Laboratory Medicine 2017;32(4):119-121,124
Objective To investigate the sustained release of BSA from chitosan-OREC/BSA films coated mats in vitro.Methods The negatively charged cellulose acetate (CA) fibrous mats were modified with multilayers of the positively charged chitosan or chitosan-OREC intercalated composites and the negatively charged bovine serum albumin (BSA) via electrostatic layer-by-layer (LBL) self-assembly technique.The adsorption and rinsing steps were repeated until the desired number of deposition bilayers was obtained.The in vitro BSA encapsulation and release experiments demonstrated that OREC could affect the degree of protein loading capacity and release ficiency of the LBL films coating.Results In the pH-gradient release assay,only a small amount of BSA was released from the mats in 1 h.As the time increased,the release rate of BSA of all the samples gradually went up to the maximum data within 8 h.For the samples with identical number of bilayers and record time,obvious increasing of the release amount could be seen in pH 7.4,in comparison with pH 1.2.Besides,doubling bilayers film-coated mats generally.Meanwhile,it was slightly distinguishable between 5 and 5.5 as well as 10 and 10.5 bilayers (t=0.651~ 1.324,P>0.05).Interestingly,it could be seen that protein release of the chitosan-OREC/BSA films coated mats remarkably increased compared with that of chitosan/BSA films coated mats(t=2.264~ 2.305,P<0.05).Conclusion The release of protein in the initial time could be controlled by adjusting the number of deposition bilayers,the outmost layer and the composition of coating bilayers.